Objective To explore the effects of montelukast for improving pulmonary functions and airway inflammation in children patients with bronchial asthma. Methods A total of 108 children patients with bronchial asthma who were admitted to our hospital were assigned to research group and control group based on their disease conditions. The re-search group was given regular treatment and montelukast, and the control group was given regular treatment alone. Ex-amination of pulmonary functions (FEV1, FEV1/FVC and ratio of FEV1 to predicting value), changes of airway inflamma-tion factors (IL-5, IL-10 and TNF-α), eosnophils count and clinical effects before and after the treatment between the two groups of children patients were assessed. Results The differences of indices such as FEV1, FEV1/FVC and ratio of FEV1 to predicting value in the research group after the treatment were all statistically significant compared with those in the control group(P<0.05). The differences of IL-5, IL-10 and TNF-α in the research group after the treat-ment were statistically significant compared with those in the control group (P<0.05). EOS% was (4.29±1.03)% in the research group after the treatment, and the difference was statistically significant compared with that of (5.98±1.25)%in the control group (P<0.05). 79.6%of patients in the research group received an effective treatment of bronchial asthma, and the difference was statistically significant compared with that of 29.6% in the control group (P<0.05). Con-clusion Montelukast is effective in improving pulmonary functions and airway inflammation in children patients with bronchial asthma, which is worthy of clinical promotion and application.%目的：探讨孟鲁司特钠对小儿支气管哮喘患者肺功能和气道炎症的改善作用。方法选取我院收治的小儿支气管哮喘患者108例，依据病情将患者均分为研究组和对照组；研究组给予常规治疗加用孟鲁司特钠，对照组给予常规治疗。比较两组患儿治疗前和治疗后肺功能(FEV1、FEV1/FVC和FEV1占预计值)检查、气道炎症因子(IL-5、IL-10和TNF-α)水平变化、嗜酸性粒细胞计数和临床疗效等。结果治疗后研究组的FEV1、FEV1/FVC和FEV1占预计值等指标与对照组相比均具有统计学意义(P<0.05)。治疗后研究组患儿的IL-5、IL-10和TNF-α与对照组相比有统计学意义(P<0.05)。治疗后研究组EOS%为(4.29±1.03)%，与对照组(5.98±1.25)%相比差异有统计学意义(P<0.05)。79.6%的研究组患儿支气管哮喘得到显效治疗，与对照组(29.6%)相比差异有统计学意义(P<0.05)。结论孟鲁司特钠能有效改善小儿支气管哮喘患者的肺功能和气道炎症，值得临床推广使用。
展开▼
